Open Rheumatol J: Study finds weight loss should be included in treatment for obese OA patients

Compared to intermittent ceresibu therapy, this study aims to characterize the efficacy of body mass index (BMI) in the daily continuous treatment of ceresibpre-exploratory analysis of a 24-week, double-blind, parallel grouping, random, multicenter international study858 patients with knee or hip osteoarthritis (OA) were randomly treated with ongoing or intermittent treatment of Ceresib 200 mg per dayEfficacy was measured by the total score and component score of the Arthritis Index (WOMAC) of Western Ontario and McMaster University, as well as the number of flare eventsresults showed that for patients with a BMI of 30 kg / m (2) (1.33 vs 4.85; p0.016), the minimum two-multiplier average increase (deterioration) of the total WOMAC score in the continuous treatment group was significantly lower than that of the intermittent treatment group with a BMI of 30 kg / m (2) (1.84 vs 5.12; pIn the continuous and intermittent groups, patients with a BMI of 30 kg / m (2) had a greater deterioration than those with a BMI of 30 kg / m (2)BMI 30 kg / m (2) (0.55 vs 0.88; p 0.0001) and s30kg / m (2) (0.54 vs 0.97; In patients with p 0.0001), there were fewer flares in the continuous treatment group than in the intermittent groupThere was no difference in adverse reactions to BMI in the two groups, the results show that the total WOMAC score and the number of flares are assessed ,?? Patients with a BMI of 30 kg / m (2) were significantly more effective than intermittent use of patients with a BMI of 30 kg / m (2)These data suggest that weight loss is important as part of treatment for obese OA patients